HealthEquity (NASDAQ:HQY – Get Free Report) had its price target upped by analysts at Royal Bank Of Canada from $100.00 to $108.00 in a report released on Friday,Benzinga reports. The firm currently has an “outperform” rating on the stock. Royal Bank Of Canada’s price target suggests a potential upside of 22.97% from the company’s current price.
A number of other research firms have also issued reports on HQY. Raymond James Financial set a $100.00 target price on HealthEquity in a report on Tuesday, February 17th. Barclays dropped their price target on HealthEquity from $118.00 to $110.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 18th. KeyCorp reaffirmed an “overweight” rating on shares of HealthEquity in a research note on Tuesday. BMO Capital Markets raised HealthEquity from a “market perform” rating to an “outperform” rating and lifted their target price for the company from $85.00 to $105.00 in a research note on Thursday, April 9th. Finally, Barrington Research reaffirmed an “outperform” rating and set a $110.00 target price on shares of HealthEquity in a research note on Friday, May 22nd. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $112.36.
Get Our Latest Stock Report on HealthEquity
HealthEquity Stock Performance
HealthEquity (NASDAQ:HQY – Get Free Report) last posted its earnings results on Thursday, May 28th. The company reported $1.24 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.11 by $0.13. HealthEquity had a return on equity of 13.86% and a net margin of 16.39%.The company had revenue of $354.64 million for the quarter, compared to analysts’ expectations of $352.02 million. HealthEquity’s revenue was up 7.2% compared to the same quarter last year. HealthEquity has set its FY 2027 guidance at 2.880-2.950 EPS. Research analysts anticipate that HealthEquity will post 3.84 EPS for the current year.
Institutional Inflows and Outflows
Institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its position in shares of HealthEquity by 2.9% during the third quarter. Vanguard Group Inc. now owns 8,746,255 shares of the company’s stock valued at $828,883,000 after purchasing an additional 243,549 shares during the period. Wasatch Advisors LP grew its position in HealthEquity by 9.3% in the first quarter. Wasatch Advisors LP now owns 7,202,934 shares of the company’s stock valued at $601,949,000 after acquiring an additional 613,288 shares during the period. Geode Capital Management LLC grew its position in HealthEquity by 0.3% in the fourth quarter. Geode Capital Management LLC now owns 2,201,232 shares of the company’s stock valued at $201,685,000 after acquiring an additional 5,671 shares during the period. Westfield Capital Management Co. LP grew its position in HealthEquity by 13.7% in the fourth quarter. Westfield Capital Management Co. LP now owns 1,952,452 shares of the company’s stock valued at $178,864,000 after acquiring an additional 235,794 shares during the period. Finally, William Blair Investment Management LLC acquired a new position in shares of HealthEquity during the fourth quarter valued at $169,956,000. 99.55% of the stock is owned by institutional investors.
Key Headlines Impacting HealthEquity
Here are the key news stories impacting HealthEquity this week:
- Positive Sentiment: HealthEquity reported Q1 EPS of $1.24, ahead of the $1.11 estimate, on revenue of $354.64 million versus $352.02 million expected; revenue rose 7.2% year over year. HealthEquity earnings report and transcript
- Positive Sentiment: The company said it raised its repurchase program by $1.0 billion, which can signal confidence in future cash generation and provide support for the share price. HealthEquity financial results and guidance press release
- Positive Sentiment: HealthEquity raised its FY 2027 revenue outlook to $1.41 billion-$1.42 billion, reinforcing the view that growth is continuing despite a mixed broader market backdrop. Seeking Alpha article on FY 2027 revenue and buyback
- Neutral Sentiment: Investors are also parsing the earnings call transcript and post-earnings coverage for management commentary on margins, guidance, and demand trends. HQY Q1 2027 earnings call transcript
- Negative Sentiment: The main caution is that FY 2027 EPS guidance of 2.880-2.950 was below the much higher consensus figure cited in the news flow, which could temper enthusiasm if investors focus on profit expectations rather than revenue growth. HealthEquity financial results and guidance press release
About HealthEquity
HealthEquity, Inc (NASDAQ: HQY) is a leading administrator of consumer-directed health accounts and related benefit solutions in the United States. Founded in 2002 and headquartered in Draper, Utah, the company specializes in health savings accounts (HSAs) and offers complementary services such as flexible spending accounts (FSAs), health reimbursement arrangements (HRAs), COBRA administration and commuter benefits. Through its technology-driven platform, HealthEquity enables employers, health plans and individuals to streamline account management, improve cost transparency and encourage more informed healthcare spending.
Serving millions of members across all 50 states, HealthEquity leverages an open-architecture ecosystem that integrates with health plans, payroll providers and financial institutions.
Recommended Stories
- Five stocks we like better than HealthEquity
- Shares Fall, Targets Rise—Markets and Analysts Diverge on Synopsys
- Salesforce Stock Finds Support as AI Momentum Builds
- Dollar Tree Keeps Winning After Family Dollar Divorce
- Apple’s Agentic AI Plans Could Be Its Biggest Growth Story Yet
Receive News & Ratings for HealthEquity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HealthEquity and related companies with MarketBeat.com's FREE daily email newsletter.
